Sobi’s emapalumab offers control of MAS symptoms in Still’s disease

Swedish Orphan Biovitrum (STO: SOBI), the Nordic biotech also known as Sobi, is presenting new research on the use of emapalumab in patients with macrophage activation syndrome (MAS) in Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still’s disease (AOSD) who had an inadequate response to high-dose glucocorticoids (GCs).

The data, which are being presented at the American College of Rheumatology (ACR) Convergence in Washington DC, USA, were pooled from two open-label, single-arm interventional studies, the Phase III NI-0501-14 trial, and NI-0501-06, including 39 patients with MAS. 

Lydia Abad-Franch, Sobi’s head of research and development and medical affairs, and chief medical officer, said: “MAS in Still’s disease is a severe condition characterized by intense hyperinflammation and multiple organ failure. Those affected, including young children, often experience high fevers, liver and spleen enlargement, severe cytopenias, and neurological symptoms.